Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Inc.

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Amicus, with a price target of $21.00. Kluska cove...

Current Quarter	$0.08	Next Quarter	$0.07
Current Year	$0.1	Next Year	$0.43
QoQ Growth	-12.5%	YoY Growth	+330.0%
3Y EPS CAGR	+41.9%	Target Price	$15.64
Consensus	Buy	Upside	+63.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FOLD	$9.56	+1.16%	4.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FOLD	$9.56	+1.2%	4.02M
3
4
5
6

FOLD

FOLD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Amicus Therapeutics Inc. Data in Excel

Get Amicus Therapeutics Inc. Data in Excel